Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →🤖 ML Fraud Detection Score: 93%
Machine learning model identifies prescribing patterns consistent with confirmed fraud cases. This is a statistical indicator, not an accusation.
Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
10,139
Total Claims
$718K
Drug Cost
416
Beneficiaries
$1,726
Cost/Patient
Risk Score Breakdown 36/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
+405%
Opioid rate vs peers
13.0% vs 2.6% avg
+62%
Cost per patient vs peers
$1,726 vs $1,068 avg
-21%
Brand preference vs peers
7.1% vs 9.0% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
ML fraud detection score of 93% indicates prescribing patterns with significant similarity to confirmed fraud cases. 19 out of 20 decision trees flagged this provider.
Opioid rate is 405% above Family Practice peers. This is a significant deviation that may reflect a specialized patient population or concerning prescribing patterns.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
13.0%
Opioid Rate
1,321
Opioid Claims
$37K
Opioid Cost
9.5%
Long-Acting Rate
Brand vs Generic
Brand: 717 claims · $500K
Generic: 9,343 claims · $214K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Etanercept | 13 | $98K |
| Apixaban | 47 | $51K |
| Dulaglutide | 36 | $40K |
| Lipase/Protease/Amylase | 32 | $38K |
| Tirzepatide | 12 | $22K |
| Empagliflozin | 19 | $21K |
| Tiotropium Bromide | 15 | $19K |
| Ipratropium/Albuterol Sulfate | 28 | $17K |
| Rivaroxaban | 16 | $15K |
| Semaglutide | 12 | $13K |
| Insulin Glargine,hum.Rec.Anlog | 16 | $12K |
| Oxycodone Myristate | 12 | $11K |
| Insulin Nph Human Isophane | 20 | $11K |
| Ezetimibe | 169 | $10K |
| Insulin Glargine,hum.Rec.Anlog | 13 | $9,257 |
Prescribing Profile
Patient Profile
71
Avg Age
56%
Female
1.42
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About